Haemophilia care: the only constant is change
- PMID: 34340257
- PMCID: PMC8939393
- DOI: 10.1111/bjh.17661
Haemophilia care: the only constant is change
Conflict of interest statement
Conflict of interest
Benjamin J. Samelson-Jones has been a consultant for Pfizer, Bayer, Genentech, Frontera and Cabaletta and serves on the Scientific Advisory Board of GeneVentiv. Lindsey A. George has been a consultant for Pfizer, Bayer, CSL Behring and serves on the Data Monitoring Committee Advisory Board of Avrobio. For both Benjamin J. Samelson-Jones and Lindsey A. George, fees are provided to The Children’s Hospital of Philadelphia where they practice for study participation from Spark Therapeutics and Pfizer.
Comment on
- 
  
  Haemophilia: factoring in new therapies.Br J Haematol. 2021 Sep;194(5):835-850. doi: 10.1111/bjh.17580. Epub 2021 Jul 28. Br J Haematol. 2021. PMID: 34322873 Review.
References
- 
    - Birch CL. Hemophilia, clinical and genetic aspects. Illinois Monogr Med Sci 1937;1:1–151.
 
- 
    - Lannoy N, Hermans C. The ‘royal disease’–haemophilia A or B? A haematological mystery is finally solved. Haemophilia. 2010;16:843–7. - PubMed
 
- 
    - Fassel H, McGuinn C. Hemophilia: Factoring in New Therapies. Br J Haematol. 2021;194:835–50. - PubMed
 
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
- Full Text Sources
- Medical
 
        